Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477160 · ClinicalTrials.gov registry record · Phase 1
A Study of STAR-0215 in Healthy Adult Participants
A Phase 1 study, sponsored by Astria Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05477160 is a Phase 1 study that has completed, run by Astria Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT05477160, a Phase 1 study, has completed, sponsored by Astria Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adult participants.
Interventions
- DRUG Placebo (SC)
- DRUG Placebo (IV)
- DRUG STAR-0215 (SC)
- DRUG STAR-0215 (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05477160
The ClinicalTrials.gov registry entry for NCT05477160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astria Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (SC) is the first listed.
NCT05477160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05477160 about?
NCT05477160 is a clinical study titled "A Study of STAR-0215 in Healthy Adult Participants". This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adul...
What is the current status of trial NCT05477160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2022-07-27. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT05477160?
The interventions under investigation include: Placebo (SC) (DRUG), Placebo (IV) (DRUG), STAR-0215 (SC) (DRUG), STAR-0215 (IV) (DRUG).
Who is sponsoring clinical trial NCT05477160?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.